- Conditions
- Schizophrenia
- Interventions
- SEP-363856 50mg, SEP-363856 75mg, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Anaheim, California • Bellflower, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Schizophrenia
- Interventions
- SEP363856, quetiapine XR
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 18
- States / cities
- Cerritos, California • Oakland, California • Oceanside, California + 15 more
- Conditions
- Parkinson Disease Psychosis
- Interventions
- SEP-363856, Placebo capsule
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 55 Years to 105 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 24
- States / cities
- Fresno, California • Los Angeles, California • Riverside, California + 19 more
- Conditions
- Schizophrenia
- Interventions
- SEP-363856
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 13 Years to 65 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 19 more
- Conditions
- Schizophrenia
- Interventions
- SEP-363856 75mg, SEP-363856 100mg, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 18
- States / cities
- Rogers, Arkansas • Anaheim, California • Bellflower, California + 15 more